Azathioprine. Safety profile in multiple sclerosis patients
β Scribed by L. La Mantia; N. Mascoli; C. Milanese
- Publisher
- Springer Milan
- Year
- 2007
- Tongue
- English
- Weight
- 92 KB
- Volume
- 28
- Category
- Article
- ISSN
- 1590-1874
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract In vitro immune function was assessed in patients with multiple sclerosis (MS) who were receiving Imuran therapy, in untreated MS patients, and in controls. In untreated stable MS patients, concanavalin A (Con A)βdriven mitogenic reactivity (T effector function) and Con Aβinduced suppre
The results of a prospective, long-term controlled study on the treatment of multiple sclerosis with azathioprine are reported. The effect of a daily 2 mg/kg body weight dosage on 56 randomly chosen patients with multiple sclerosis is compared with a non-treated control group of 51 randomly selected